Targeted-therapy and imaging response

A new paradigm for clinical evaluation?

Amalia Milano, Francesco Perri, Andrea Ciarmiello, Francesco Caponigro

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Clinical management of patients with malignant tumors has dramatically changed over the last years with the introduction of novel therapeutics, such as receptor-targeted therapies, downstream effectors and antiangiogenic compounds. This has created a need to re-evaluate the existing criteria used to assess treatment response. Emerging diagnostic techniques, combining functional and structural data may play a relevant role in planning new treatment strategies in individual cancer patients. In the new scenario where biological treatment results in stable disease, standard Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria have limitations. Moreover, functional 18-fluorodeoxyglucose ( 18FDG)-positron emission tomography (PET) imaging provides an additional tool to assess tumor activity, particularly consistent in some settings, such as Gastro Intestinal Solid Tumors (GIST), hepatocarcinoma, nonsmall lung cancer, and colorectal cancer. The integration of 18FDG-PET and computed tomography (CT) enhances the evaluation of oncologic patients treated with molecularly targeted drugs, and accelerates drug development in many types of tumors.

Original languageEnglish
Pages (from-to)259-265
Number of pages7
JournalReviews on Recent Clinical Trials
Volume6
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Neoplasms
Therapeutics
Pharmaceutical Preparations
Positron-Emission Tomography
Colorectal Neoplasms
Lung Neoplasms
Response Evaluation Criteria in Solid Tumors
Positron Emission Tomography Computed Tomography

Keywords

  • CT
  • PET
  • RECIST 1.1 criteria
  • RECISTcriteria
  • Solid tumors
  • Targeted-therapies

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Targeted-therapy and imaging response : A new paradigm for clinical evaluation? / Milano, Amalia; Perri, Francesco; Ciarmiello, Andrea; Caponigro, Francesco.

In: Reviews on Recent Clinical Trials, Vol. 6, No. 3, 09.2011, p. 259-265.

Research output: Contribution to journalArticle

Milano, Amalia ; Perri, Francesco ; Ciarmiello, Andrea ; Caponigro, Francesco. / Targeted-therapy and imaging response : A new paradigm for clinical evaluation?. In: Reviews on Recent Clinical Trials. 2011 ; Vol. 6, No. 3. pp. 259-265.
@article{2a63851b3c9540c9bf9d8f26fe389d0d,
title = "Targeted-therapy and imaging response: A new paradigm for clinical evaluation?",
abstract = "Clinical management of patients with malignant tumors has dramatically changed over the last years with the introduction of novel therapeutics, such as receptor-targeted therapies, downstream effectors and antiangiogenic compounds. This has created a need to re-evaluate the existing criteria used to assess treatment response. Emerging diagnostic techniques, combining functional and structural data may play a relevant role in planning new treatment strategies in individual cancer patients. In the new scenario where biological treatment results in stable disease, standard Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria have limitations. Moreover, functional 18-fluorodeoxyglucose ( 18FDG)-positron emission tomography (PET) imaging provides an additional tool to assess tumor activity, particularly consistent in some settings, such as Gastro Intestinal Solid Tumors (GIST), hepatocarcinoma, nonsmall lung cancer, and colorectal cancer. The integration of 18FDG-PET and computed tomography (CT) enhances the evaluation of oncologic patients treated with molecularly targeted drugs, and accelerates drug development in many types of tumors.",
keywords = "CT, PET, RECIST 1.1 criteria, RECISTcriteria, Solid tumors, Targeted-therapies",
author = "Amalia Milano and Francesco Perri and Andrea Ciarmiello and Francesco Caponigro",
year = "2011",
month = "9",
doi = "10.2174/157488711796575540",
language = "English",
volume = "6",
pages = "259--265",
journal = "Reviews on Recent Clinical Trials",
issn = "1574-8871",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Targeted-therapy and imaging response

T2 - A new paradigm for clinical evaluation?

AU - Milano, Amalia

AU - Perri, Francesco

AU - Ciarmiello, Andrea

AU - Caponigro, Francesco

PY - 2011/9

Y1 - 2011/9

N2 - Clinical management of patients with malignant tumors has dramatically changed over the last years with the introduction of novel therapeutics, such as receptor-targeted therapies, downstream effectors and antiangiogenic compounds. This has created a need to re-evaluate the existing criteria used to assess treatment response. Emerging diagnostic techniques, combining functional and structural data may play a relevant role in planning new treatment strategies in individual cancer patients. In the new scenario where biological treatment results in stable disease, standard Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria have limitations. Moreover, functional 18-fluorodeoxyglucose ( 18FDG)-positron emission tomography (PET) imaging provides an additional tool to assess tumor activity, particularly consistent in some settings, such as Gastro Intestinal Solid Tumors (GIST), hepatocarcinoma, nonsmall lung cancer, and colorectal cancer. The integration of 18FDG-PET and computed tomography (CT) enhances the evaluation of oncologic patients treated with molecularly targeted drugs, and accelerates drug development in many types of tumors.

AB - Clinical management of patients with malignant tumors has dramatically changed over the last years with the introduction of novel therapeutics, such as receptor-targeted therapies, downstream effectors and antiangiogenic compounds. This has created a need to re-evaluate the existing criteria used to assess treatment response. Emerging diagnostic techniques, combining functional and structural data may play a relevant role in planning new treatment strategies in individual cancer patients. In the new scenario where biological treatment results in stable disease, standard Response Evaluation Criteria in Solid Tumors (RECIST) and RECIST 1.1 criteria have limitations. Moreover, functional 18-fluorodeoxyglucose ( 18FDG)-positron emission tomography (PET) imaging provides an additional tool to assess tumor activity, particularly consistent in some settings, such as Gastro Intestinal Solid Tumors (GIST), hepatocarcinoma, nonsmall lung cancer, and colorectal cancer. The integration of 18FDG-PET and computed tomography (CT) enhances the evaluation of oncologic patients treated with molecularly targeted drugs, and accelerates drug development in many types of tumors.

KW - CT

KW - PET

KW - RECIST 1.1 criteria

KW - RECISTcriteria

KW - Solid tumors

KW - Targeted-therapies

UR - http://www.scopus.com/inward/record.url?scp=80051763253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051763253&partnerID=8YFLogxK

U2 - 10.2174/157488711796575540

DO - 10.2174/157488711796575540

M3 - Article

VL - 6

SP - 259

EP - 265

JO - Reviews on Recent Clinical Trials

JF - Reviews on Recent Clinical Trials

SN - 1574-8871

IS - 3

ER -